Endogenous glucagon‐like peptide (GLP)‐1 as alternative for GLP‐1 receptor agonists: Could this work and how?
Citations Over TimeTop 10% of 2023 papers
Abstract
In recent years, we have witnessed the many beneficial effects of glucagon-like peptide (GLP)-1 receptor agonists, including the reduction in cardiovascular risk in patients with type 2 diabetes, and the reduction of body weight in those with obesity. Increasing evidence suggests that these agents differ considerably from endogenous GLP-1 when it comes to their routes of action, although their clinical effects appear to be the same. Given the limitations of the GLP-1 receptor agonists, could it be useful to develop agents which stimulate GLP-1 release? Here we will discuss the differences and similarities between GLP-1 receptor agonists and endogenous GLP-1, and will detail how endogenous GLP-1-when stimulated appropriately-could have clinically relevant effects.
Related Papers
- → Effects of the Long-Acting Human Glucagon-Like Peptide-1 Analog Liraglutide on β-Cell Function in Normal Living Conditions(2007)83 cited
- Liraglutide: A human GLP-1 analogue for the treatment of type 2 diabetes(2009)
- → Glucagon-like peptide-1 (GCG; GLP-1); GLP-1 receptor (GLP1R; GLP-1R)(2009)1 cited
- → Human glucagon-like peptide-1 analogue-Liraglutide(2008)
- → Hot off the press: Insight to the cardioprotective effects of GLP-1 (glucagon-like peptide-1) analog liraglutide(2022)